The trial compared the activity of atezolizumab with docetaxel and found that patients receiving atezolizumab significantly improved OS in comparison to patients receiving docetaxel.38 Regardless of expression of PD-L1, OAK (NCT02008227), another late-phase (III) trial, was carried out among NSCLC patients who had undergone a minimum of one platinum-derived treatment. This evidence concerns the gene CD274 and non-small cell lung carcinoma.